• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    USANA Health Sciences Reports First Quarter 2024 Results

    4/30/24 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 30, 2024.

    Key Financial & Operating Results

    • First quarter net sales were $228 million versus $248 million during Q1 2023, and increased 2% sequentially in constant currency.
    • First quarter diluted EPS was $0.86 as compared with $0.95 during Q1 2023.
    • Company reiterates fiscal year 2024 net sales and diluted EPS outlook of $850 million to $920 million and $2.40 to $3.00.

    Q1 2024 Financial Performance

    Consolidated Results

    Net Sales

    $228 million

    • -8% vs. Q1 2023

     

     

    • -5% constant currency vs. Q1 2023

     

     

    • +3% sequentially

     

     

    • +2% constant currency sequentially

     

     

    • -$7 million YOY FX impact, or -3%

    Diluted EPS

    $0.86

    • -9% vs. Q1 2023

     

     

    • -1% sequentially

    Active Customers

    494,000

    • +1% vs. Q1 2023

     

     

    • +2% sequentially

    "Our top line results during the first quarter were driven by a successful sales incentive in mainland China, which helped counter the seasonal slowdown that we experience during the Lunar New Year holiday," said Jim Brown, President and Chief Executive Officer. "This sales incentive helped us generate 15% year-over-year active customer growth in our largest market, as well as year-over-year and sequential quarter sales growth. Notwithstanding our solid performance in China, our first quarter results in other key markets did not meet internal expectations and we are actively working to accelerate our business in these markets during 2024.

    "During the first quarter we focused on actively engaging with our Associate leaders across the world through several live annual kickoff events, meetings, and trainings. Moreover, early in the second quarter, we hosted both our China National Sales Meeting in Xiamen, China and our Asia Pacific Convention in Kuala Lampur, Malaysia. Attendance at both events was robust and our executive team and Associate leaders came away from both events with increased excitement and motivation to grow their businesses during 2024. We will host additional Associate events throughout the year; all intended to drive further engagement with and productivity from our Associate leaders.

    "We also completed our first full quarter of operations in India and we remain excited and optimistic about this important market. We continue to work closely with our local leadership team to expand and build our presence throughout the country. Although we expect its contribution to be small in this first year, we have high expectations for steady and long-term growth in India."

    Q1 2024 Regional Results:

    Asia Pacific Region

    Net Sales

    $185 million

    • -7% vs. Q1 2023

     

     

    • -3% constant currency vs. Q1 2023

     

     

    • +5% sequentially

     

     

    • 81% of consolidated net sales

    Active Customers

    395,000

    • +2% vs. Q1 2023

     

     

    • +3% sequentially

    Asia Pacific Sub-Regions

    Greater China

    Net Sales

    $128 million

    • +3% vs. Q1 2023

     

     

    • +7% constant currency vs. Q1 2023

     

     

    • +10% sequentially

    Active Customers

    274,000

    • +13% vs. Q1 2023

     

     

    • +7% sequentially

    North Asia

    Net Sales

    $21 million

    • -28% vs. Q1 2023

     

     

    • -24% constant currency vs. Q1 2023

     

     

    • -3% sequentially

    Active Customers

    45,000

    • -17% vs. Q1 2023

     

     

    • -6% sequentially

    Southeast Asia Pacific

    Net Sales

    $36 million

    • -22% vs. Q1 2023

     

     

    • -19% constant currency vs. Q1 2023

     

     

    • -8% sequentially

    Active Customers

    76,000

    • -16% vs. Q1 2023

     

     

    • -5% sequentially

    Americas and Europe Region

    Net Sales

    $43 million

    • -12% vs. Q1 2023

     

     

    • -14% constant currency vs. Q1 2023

     

     

    • -3% sequentially

     

     

    • 19% of consolidated net sales

    Active Customers

    99,000

    • -6% vs. Q1 2023

     

     

    • -1% sequentially

    Balance Sheet and Share Repurchase Activity

    The Company generated $18 million in operating cash flow during first quarter and ended the quarter with $328 million in cash and cash equivalents while remaining essentially debt-free. The Company repurchased 194,000 shares for a total of $9 million during the quarter. As of March 30, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

    Fiscal Year 2024 Outlook

    The Company is reiterating its net sales and earnings per share outlook for fiscal year 2024, as follows:

    Fiscal Year 2024 Outlook

     

    Range

    Consolidated Net Sales

    $850 - $920 million

    Diluted EPS

    $2.40 - $3.00

    "Strength in our mainland China operations carried our first quarter results," said Doug Hekking, Chief Financial Officer. "This performance helped offset softness in many other markets where we continue to face a challenging operating environment highlighted by ongoing inflationary pressures."

    Mr. Hekking continued, "We remain committed to engaging with Associate leaders throughout each of our markets and plan to offer additional market-specific incentives throughout the year to improve sales and customer activity levels."

    Management Commentary Document and Conference Call

    For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will hold a conference call and webcast to discuss today's announcement with investors on Wednesday, May 1, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.

    Non-GAAP Financial Measures

    The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

    About USANA

    USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com.

    Safe Harbor

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

     

     

    Quarter Ended

     

     

    March 30,

    2024

     

    April 1,

    2023

     

    Net sales

    $

    227,800

     

     

    $

    248,360

     

     

    Cost of sales

     

    43,069

     

     

     

    48,519

     

     

    Gross profit

     

    184,731

     

     

     

    199,841

     

     

    Operating expenses:

     

     

     

     

    Associate incentives

     

    95,758

     

     

     

    106,070

     

     

    Selling, general and administrative

     

    64,300

     

     

     

    66,926

     

     

    Total operating expenses

     

    160,058

     

     

     

    172,996

     

     

    Earnings from operations

     

    24,673

     

     

     

    26,845

     

     

    Other income (expense):

     

     

     

     

    Interest income

     

    2,676

     

     

     

    1,775

     

     

    Interest expense

     

    (52

    )

     

     

    (31

    )

     

    Other, net

     

    (186

    )

     

     

    (88

    )

     

    Other income (expense), net

     

    2,438

     

     

     

    1,656

     

     

    Earnings before income taxes

     

    27,111

     

     

     

    28,501

     

     

    Income taxes

     

    10,574

     

     

     

    10,118

     

     

    Net earnings

    $

    16,537

     

     

    $

    18,383

     

     

     

     

     

     

     

    Earnings per common share

     

     

     

     

    Basic

    $

    0.86

     

     

    $

    0.95

     

     

    Diluted

    $

    0.86

     

     

    $

    0.95

     

     

     

     

     

     

     

    Weighted average common shares outstanding

     

     

     

     

    Basic

     

    19,174

     

     

     

    19,283

     

     

    Diluted

     

    19,302

     

     

     

    19,328

     

     

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

    (unaudited)

     

     

    As of

    March 30,

    2024

     

    As of

    December 30,

    2023

    ASSETS

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    328,336

     

    $

    330,420

    Inventories

     

    60,870

     

     

    61,454

    Prepaid expenses and other current assets

     

    31,864

     

     

    25,872

    Total current assets

     

    421,070

     

     

    417,746

    Property and equipment, net

     

    98,186

     

     

    99,814

    Goodwill

     

    16,902

     

     

    17,102

    Intangible assets, net

     

    29,105

     

     

    29,919

    Deferred tax assets

     

    11,347

     

     

    13,284

    Other assets*

     

    52,665

     

     

    54,892

    Total assets

    $

    629,275

     

    $

    632,757

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    8,266

     

    $

    10,070

    Line of credit - short term

     

    1,320

     

     

    786

    Other current liabilities

     

    103,045

     

     

    107,989

    Total current liabilities

     

    112,631

     

     

    118,845

    Deferred tax liabilities

     

    5,113

     

     

    4,552

    Other long-term liabilities

     

    11,543

     

     

    12,158

     

     

     

     

    Stockholders' equity

     

    499,988

     

     

    497,202

    Total liabilities and stockholders' equity

    $

    629,275

     

    $

    632,757

    *Other assets include noncurrent inventories of $2,893 and $3,128 as of 30-Mar-24 and 30-Dec-23, respectively. Total inventories were $63,763 and $64,582 as of 30-Mar-24 and 30-Dec-23, respectively.

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    SALES BY REGION

    (in thousands)

    (unaudited)

     

     

    Quarter Ended

     

    Change from prior

    year

     

    Percent change

     

    Currency impact on

    sales

     

    % change

    excluding currency

    impact

     

    March 30, 2024

     

    April 1, 2023

     

     

     

     

    Asia Pacific

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Greater China

    $

    127,615

     

    56.0

    %

     

    $

    123,820

     

    49.9

    %

     

    $

    3,795

     

     

    3.1

    %

     

    $

    (5,396

    )

     

    7.4

    %

    Southeast Asia Pacific

     

    36,065

     

    15.9

    %

     

    $

    46,286

     

    18.6

    %

     

     

    (10,221

    )

     

    (22.1

    %)

     

     

    (1,495

    )

     

    (18.9

    %)

    North Asia

     

    21,421

     

    9.4

    %

     

    $

    29,608

     

    11.9

    %

     

     

    (8,187

    )

     

    (27.7

    %)

     

     

    (987

    )

     

    (24.3

    %)

    Asia Pacific Total

     

    185,101

     

    81.3

    %

     

     

    199,714

     

    80.4

    %

     

     

    (14,613

    )

     

    (7.3

    %)

     

     

    (7,878

    )

     

    (3.4

    %)

    Americas and Europe

     

    42,699

     

    18.7

    %

     

     

    48,646

     

    19.6

    %

     

     

    (5,947

    )

     

    (12.2

    %)

     

     

    635

     

     

    (13.5

    %)

     

    $

    227,800

     

    100.0

    %

     

    $

    248,360

     

    100.0

    %

     

    $

    (20,560

    )

     

    (8.3

    %)

     

    $

    (7,243

    )

     

    (5.4

    %)

    USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES

    ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION

    (unaudited)

     

    Active Associates by Region(1)

    (unaudited)

     

    As of

    March 30, 2024

     

    As of

    April 1, 2023

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    71,000

     

    36.1

    %

     

    74,000

     

    34.1

    %

    Southeast Asia Pacific

    51,000

     

    25.9

    %

     

    61,000

     

    28.1

    %

    North Asia

    30,000

     

    15.2

    %

     

    35,000

     

    16.1

    %

    Asia Pacific Total

    152,000

     

    77.2

    %

     

    170,000

     

    78.3

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    45,000

     

    22.8

    %

     

    47,000

     

    21.7

    %

     

    197,000

     

    100.0

    %

     

    217,000

     

    100.0

    %

    Active Preferred Customers by Region(2)

    (unaudited)

     

    As of

    March 30, 2024

     

    As of

    April 1, 2023

    Asia Pacific:

     

     

     

     

     

     

     

    Greater China

    203,000

     

    68.3

    %

     

    168,000

     

    61.3

    %

    Southeast Asia Pacific

    25,000

     

    8.4

    %

     

    29,000

     

    10.6

    %

    North Asia

    15,000

     

    5.1

    %

     

    19,000

     

    6.9

    %

    Asia Pacific Total

    243,000

     

    81.8

    %

     

    216,000

     

    78.8

    %

     

     

     

     

     

     

     

     

    Americas and Europe

    54,000

     

    18.2

    %

     

    58,000

     

    21.2

    %

     

    297,000

     

    100.0

    %

     

    274,000

     

    100.0

    %

    (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

    (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240430764505/en/

    Get the next $USNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Extends Partnership with World-Famous Jamaican Bobsled Team to Help Fuel Their Olympic Dreams

    Partnership will now run through two more Olympic cycles SALT LAKE CITY, Dec. 4, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a leader in global nutrition, is proud to announce the extension of its partnership with the world-famous Jamaica Bobsleigh and Skeleton Federation (JBSF) through two additional Olympic cycles. USANA will continue providing high-quality nutritional products to support the team's training and performance, while the USANA logo will be featured on the team's bobsled, helmets, and racing suits. To learn more about how USANA fuels the best athletes in t

    12/4/25 7:07:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    On National "Make-a-Gift Day," Kevin Guest Says the Most Meaningful Gifts Are the Ones Money Can't Buy

    Creative gestures and shared experiences form the foundation of lasting love. SALT LAKE CITY, Dec. 3, 2025 /PRNewswire/ -- National Make a Gift Day (Dec. 3) is a call to generosity and intentionality, encouraging people to craft something meaningful for someone they care about. For Executive Chairman of USANA Health Sciences and author Kevin Guest, that spirit of thoughtfulness is deeply personal—and romantic. Long before he led an international company or became a bestselling author, Guest was a college student trying to win the heart of a woman who would eventually become hi

    12/3/25 7:03:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Proven Power for Strong Bone Support--USANA's MagneCal D Earns ConsumerLab.com Seal of Approval

    SALT LAKE CITY, Nov. 11, 2025 /PRNewswire/ -- USANA (NYSE:USNA), the global leader in cellular nutrition, is thrilled to announce that its fan-favorite MagneCal D supplement has officially earned the coveted ConsumerLab.com Seal of Approval—a gold-standard recognition for purity, potency, and scientific excellence.* With millions of Americans looking for ways to maintain their bone density, getting enough calcium, magnesium, and vitamin D isn't just a good idea—it's essential. That's where MagneCal D comes in, combining powerful nutrients to help maintain strong bones, keep yo

    11/11/25 7:25:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    SEC Form 10-Q filed by USANA Health Sciences Inc.

    10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    11/5/25 5:11:01 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    10/22/25 4:12:42 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    10/9/25 4:10:36 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF INFORMATION OFFICER Benedict Peter sold $56,001 worth of shares (2,673 units at $20.95), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    12/11/25 11:21:37 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF SALES OFFICER Mulham David Mulham sold $18,333 worth of shares (873 units at $21.00), decreasing direct ownership by 9% to 8,387 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    12/11/25 11:25:25 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Winssinger Frederic J sold $38,420 worth of shares (2,000 units at $19.21), decreasing direct ownership by 25% to 5,986 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    11/10/25 5:20:51 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Third Quarter 2025 Results and Updates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal third quarter ended September 27, 2025. Key Financial Results Third Quarter 2025 vs. Third Quarter 2024 Net sales of $214 million versus $200 million, representing 7% year-over-year growth. Net loss of -$6.5 million versus net earnings of $10.6 million. Diluted EPS of -$0.36 as compared with $0.56. Adjusted diluted EPS(1) of -$0.15 as compared with $0.56. Adjusted EBITDA(2) of $13.8 million versus $24.6 million. Direct selling Active Customers of 388,000 versus 452,000. Hiya Active Monthly Subscribers of 193,400. Q3 2025 Financial Performance Consolidated Results

    10/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Updates the Timing of the Release of Third Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) ("the Company," "USANA") today announced that it has updated the timing of the release of its third quarter 2025 financial results, which had previously been scheduled for Tuesday, October 21, 2025. The Company will now report third quarter 2025 financial results after the close of market on Wednesday, October 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the follow

    10/20/25 5:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Provides Preliminary Third Quarter Results

    USANA Health Sciences, Inc. (NYSE:USNA) today announced preliminary results for the third quarter ended September 27, 2025. The Company anticipates third quarter 2025 net sales will be approximately $214 million, which compares with $200 million in the prior-year period. Earnings from operations are expected to be $1.2 million for the current-year quarter, or 0.6% of net sales, as compared to $15.6 million in the third quarter of 2024. "Third quarter operating results came in below expectations, primarily due to softer-than-expected sales and Brand Partner productivity during the rollout of our enhanced Brand Partner compensation plan," said Jim Brown, President and Chief Executive Office

    10/9/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Appoints New Chief Scientific Officer

    Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

    1/22/25 7:07:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care